Domankevich, Vered
Cohen, Adi
Efrati, Margalit
Schmidt, Michael
Rammensee, Hans-Georg
Nair, Sujit S.
Tewari, Ashutosh
Kelson, Itzhak
Keisari, Yona
Funding for this research was provided by:
Israel Innovation Authority (61011)
Article History
Received: 5 March 2019
Accepted: 10 October 2019
First Online: 22 October 2019
Compliance with ethical standards
:
: Yona Keisari and Itzhak Kelson serve as officers at Alpha Tau Medical Ltd. Tel Aviv, Israel. Hans-Georg Rammensee shares the patent for XS15. All other authors declare that they have no conflict of interest.
: Experiments were performed in accordance with Israeli government and Tel Aviv University institute guidelines and regulations (Ethical committee permit no. 01-17-93).
: Animals were obtained from Envigo (Jerusalem, Israel).
: The CT26 cell line is an N-nitroso-N-methylurethane (NNMU)-induced, undifferentiated colon carcinoma cell line that was purchased from the American Type Culture Collection (ATCC, CT26.WTATCC<sup>®</sup> CRL-2638™) in 2015. Cells cryopreserved at their third passage following purchase were used for the experiments. The DA3 cell line is a dimethylbenzanthracene (DMBA)-induced, undifferentiated breast adenocarcinoma cell line. The cell line was a gift from Prof. Ilan Tsarfati [CitationRef removed]. Both cell lines were tested for mycoplasma and were found to be mycoplasma free. Both cell lines were authenticated using short tandem repeat (STR) profiling (CellCheck™, IDEXX BioAnalytics, USA). No mammalian interspecies contamination was detected. The STR DNA profile of DA3 cells was generated, for the first time, as follows: MCA-4-2: 21.3, 22.3; MCA-5-5: 13, 14; MCA-6-4: 18, 20; MCA-6-7: 12, 13; MCA-9-2: 14, 15; MCA-12-1: 16; MCA-15-3: 22.3; MCA-18-3: 19, 20; MCA-X-1: 24.